BioSpace News Archive

The U.S. Food and Drug Administration (FDA) has approved Jardiance.

Kestra Medical Technologies is launching the ASSURE Clinician Experience (ACE), a program that lets electrophysiology and cardiology professionals wear and simulate use of the ASSURE® Wearable Cardioverter Defibrillator (WCD) system at The Heart Rhythm Society #HRX2023 global health and technology conference, September 21-23, 2023 in Seattle, WA.

Brandon Cuevas has been selected as executive vice president for Kaiser Foundation Health Plan with national accountability for health plan strategy, capabilities, and operations, effective October 1, 2023.

Skye Bioscience, Inc. (OTCQB: SKYED) (“Skye” or the “Company”), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes

Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) following a favorable vote for ABRYSVO™ [Respiratory Syncytial Virus Vaccine], the company’s bivalent RSV prefusion F (RSVpreF) vaccine, as a maternal immunization.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets.

Achilles Therapeutics plc disclosed that the Company received notice on September 20, 2023 from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s American Depositary Shares on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450.

Matinas BioPharma announced that it has received a deficiency letter from NYSE American LLC stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003 of the NYSE American Company Guide.

Coherus BioSciences, Inc., announced that effective September 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 109,000 shares of the common stock of the Company to six newly hired employees with a per share exercise price of $4.51, the closing trading price on the grant date.